Lung Adenocarcinoma Overview

Save information for later
Sign Up

Learn About Lung Adenocarcinoma

View Main Condition: Non-Small Cell Lung Cancer (NSCLC)

What is the definition of Lung Adenocarcinoma?
Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing.
What are the alternative names for Lung Adenocarcinoma?
  • Lung adenocarcinoma
Who are the top Lung Adenocarcinoma Local Doctors?
Elite in Lung Adenocarcinoma
Dr. Ravi Salgia
Oncology
Elite in Lung Adenocarcinoma
Dr. Ravi Salgia
Oncology

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
626-256-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravi Salgia is an Oncologist in Duarte, California. Dr. Salgia is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Gastrostomy.

Elite in Lung Adenocarcinoma
Dr. Vamsidhar Velcheti
Hematology Oncology | Oncology | Hematology
Elite in Lung Adenocarcinoma
Dr. Vamsidhar Velcheti
Hematology Oncology | Oncology | Hematology

New York University

550 1st Ave, 
New York, NY 
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vamsidhar Velcheti is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Velcheti is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Lung Adenocarcinoma
Dr. Harvey I. Pass
Thoracic Surgery
Elite in Lung Adenocarcinoma
Dr. Harvey I. Pass
Thoracic Surgery
530 1st Ave, Suite 9v, 
New York, NY 
212-263-7365
Languages Spoken:
English
See accepted insurances

Harvey Pass is a Thoracic Surgeon in New York, New York. Dr. Pass is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Mesothelioma, Lung Cancer, Lung Nodules, Advanced Bronchoscopy, and Thymectomy.

View All Doctors
What are the latest Lung Adenocarcinoma Clinical Trials?
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Who is this study for: Patients with PD-L1-negative, advanced non-small cell lung cancer
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Procedure, Biological, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed
Study Phase: Phase 2/Phase 3

Summary: This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary s...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Who is this study for: Patients with stage III non-squamous non-small cell lung cancer
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cisplatin, Durvalumab, Methoxyamine, Pemetrexed
Study Phase: Phase 2

Summary: This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agen...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center